Abstracts tagged "Late-Breaking 2016"

Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…
Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Keith Sullivan¹, Lynette Keyes-Elstein², Peter McSweeney³, Ashley Pinckney², Beverly Welch⁴, Maureen D Mayes⁵, Richard Nash³, Leslie J. Crofford⁶, Sharon Castina², Linda Griffith⁷, Ellen Goldmuntz⁸ and Daniel E. Furst⁹, ¹Duke University, Durham, NC, ²Rho, Inc, Chapel Hill, NC, ³Colorado Blood Cancer Institute, Denver, CO, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine, Vanderbilt University Medical Center, Nasville, TN, ⁷NIAID, NIH, Bethesda, MD, ⁸NIAID, National Institutes of Health, Bethesda, MD, ⁹David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…
Abstract Number: 7L • 2016 ACR/ARHP Annual Meeting
Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon K. Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁵ and Lhanoo Gunawardhana⁴, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL, ⁵RRD International, Rockville, MD

Background/Purpose: No clinical trials have previously investigated the frequency of acute flares in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 8L • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
Anthony A. Amato¹, Umesh Badrising², Olivier Benveniste³, Merrilee Needham⁴, Hector Chinoy⁵, Min Wu⁶, Barbara Koumaras⁶, Ana de Vera⁷, Dimitris A. Papanicolaou⁶ and Michael G. Hanna⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Department of Neurology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Pitié-Salpêtrière Hospital, Pierre et Marie-Curie University, Paris, France, ⁴Fiona Stanley Hospital, IIID Murdoch University and Notre Dame University, Perth, Australia, ⁵Centre for Musculoskeletal Research, NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom

Background/Purpose: Bimagrumab (BYM338) is a novel fully human monoclonal antibody that binds competitively to activin type II receptors with greater affinity than natural inhibitory ligands…
Abstract Number: 9L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial
Fabrizio De Benedetti¹, Joost Frenkel², Inmaculada Calvo³, Marco Gattorno⁴, Michel Moutschen⁵, Pierre Quartier⁶, Ozgur Kasapcopur⁷, Seza Ozen⁸, Jordi Anton⁹, Isabelle Koné-Paut¹⁰, Helen Lachmann¹¹, Hal M. Hoffman¹², Eldad Ben-Chetrit¹³, Anna Shcherbina¹⁴, Michaël Hofer¹⁵, Philip J Hashkes¹⁶, Andrew Zeft¹⁷, Karine Lheritier¹⁸, Yankun Gong¹⁹, Antonio Speziale¹⁸ and Guido Junge¹⁸, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology, Hospital Universitario i Politecnic La Fe, Valencia, Spain, ⁴Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁵C.H.U. Sart-Tilman, Liege, Belgium, ⁶Necker-Enfants Malades Hospital, Paris, France, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Children's Hospital, Ankara, Turkey, ⁹Hospital Sant Joan de Déu, Barcelona, Spain, ¹⁰Department of Paediatric Rheumatology, Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹¹UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹²University of California, San Diego, La Jolla, CA, ¹³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ¹⁴Immunology, Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation, ¹⁵Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Lausanne, Switzerland, ¹⁶Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, ¹⁷Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁸Novartis Pharma AG, Basel, Switzerland, ¹⁹Beijing Novartis Pharma Co. Ltd., Beijing, China

Background/Purpose: Evidence points to the role of abnormal IL-1β production in familial Mediterranean fever (FMF), hyper-immunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) and TNF receptor-associated periodic…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting
BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
Kathleen Gillooly¹, Yifan Zhang¹, Xiaoxia Yang¹, Adriana Zupa-Fernandez¹, Lihong Cheng¹, Joann Strnad¹, Mark Cunningham², Elizabeth Heimrich¹, Xiadi Zhou¹, Jing Chen³, Charu Chaudhry³, Sha Li³, Kim McIntyre¹, Julie Carman⁴, Ryan Moslin⁵, Stephen Wrobleski⁵, David Weinstein⁵ and James Burke¹, ¹Immunosciences Discovery Biology, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³Leads Discovery & Optimization, Bristol-Myers Squibb, Princeton, NJ, ⁴Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ⁵Immunosciences Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ

Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…
Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Joan T. Merrill¹, Daniel J. Wallace², Stephen Wax³, Amy Kao⁴, Patricia Fraser⁴, Wai Chin⁴ and David A. Isenberg⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of California Los Angeles, Los Angeles, CA, ³EMD Serono, BIllerica, MA, ⁴EMD Serono, Billerica, MA, ⁵University College Hospital, London, London, United Kingdom

Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Jens Humrich¹, Caroline von Spee-Mayer², Elise Siegert³, Angelika Rose², Martina Bertolo⁴, Philipp Enghard⁵, Falk Hiepe⁶, Tobias Alexander⁷, Eugen Feist⁸, Andreas Radbruch⁹, Gerd R. Burmester¹⁰ and Gabriela Riemekasten¹¹, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁶Charité – Universitätsmedizin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Deutsches Rheumaforschungszentrum, Berlin, Germany, ¹⁰Charité – University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 14L • 2016 ACR/ARHP Annual Meeting
Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases
Shing Law¹, Robert W. Simms² and Harrison W. Farber³, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Pulmonary Center, Boston University Medical Center, Boston, MA

Background/Purpose: Intravenous prostanoid therapy is recommended for severe systemic sclerosis related digital vasculopathy. Evidence to support this recommendation is limited. Our objective is to evaluate…
Abstract Number: 15L • 2016 ACR/ARHP Annual Meeting
Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Alexandra Zanin-Zhorov¹, Jonathan Weiss¹, Alissa Trzeciak¹, Carmen Arencibia¹, Seetharam Polimera¹, Wei Chen¹, Jingya Zhang¹, Melanie Nyuydzefe¹, Judilyn Fuentes-Duculan², Kathleen Bonifacio², Norma Kunjravia², Inna Cueto², Mark Berger¹, James Krueger², Samuel Waksal¹ and John Ryan¹, ¹Kadmon, New York, NY, ²Rockefeller University, New York, NY

Background/Purpose: Rho-associated kinase 2 (ROCK2) was shown to be implicated in regulation of autoimmunity in mice and humans1. Previous findings demonstrated that oral administration of…
Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Pascal Cohen³, Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and French Vasculitis Study Group, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹CH Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³CHU Cavale Blanche, Brest, Brest, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹Service de Médecine Interne et Maladies Infectieuses, CHU de Bordeaux, Pessac, France, ²⁰Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 17L • 2016 ACR/ARHP Annual Meeting
Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
David Saadoun¹, yasmina ferfar¹, AS Bouyer², laurent alric³, christophe hezode⁴, SN Si Ahmed⁵, L Musset⁶, Luc De Saint Martin Pernot⁷, SN Pol⁸, Dominique Larrey⁹, T Poynard¹⁰ and Patrice Cacoub², ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, paris, France, ³Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse, toulouse, France, ⁴Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil, creteil, France, ⁵Department of Hepatology, Hôpital Orléans, Orléans, Orleans, France, ⁶Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, paris, France, ⁷Department of internal medicine, CHRU Brest, Brest, France, ⁸Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁹Department of hepatology, CHRU Montpellier, France, montpellier, France, ¹⁰Department of Hepatology, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, paris, France

Background/Purpose: Hepatitis C virus (HCV) is the aetiological agent for most cases of cryoglobulinemia vasculitis. Interferon containing regimens are associated with important side effects and…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].